First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC).
Daniel Yick Chin Heng(University of Calgary), Toni K. Choueiri(Harvard University), Min‐Han Tan(National Cancer Centre Singapore), Sumanta K. Pal(City of Hope), Aristotelis Bamias(National and Kapodistrian University of Athens), Lauren C. Harshman(Dana-Farber Cancer Institute), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Scott North, Sun Young Rha(Yonsei University), Jennifer J. Knox(National Cancer Center), Nils Kroeger(Universitätsmedizin Greifswald), Ulka N. Vaishampayan(University of Michigan), Lori Wood(Dalhousie University), Takeshi Yuasa(Japanese Foundation For Cancer Research), Sandy Srinivas(Stanford University), Mary J. MacKenzie(Cancer Care Ontario), Neeraj Agarwal(University of Utah), Jae‐Lyun Lee(Ulsan College), Brian I. Rini(Vanderbilt University Medical Center)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k